| 西妥昔单抗联合化疗在结直肠癌中的回顾性研究 |
| |
| 作者单位： | [1]Department of GI Oncology, Peking University, School of Oncology, Beijing Cancer Hospital ＆ Institute, Beijing 100036, China [2]Department of General Surgery, Beijing Youyi Hospital, Beijing 100036, China |
| |
| 摘 要： | ![]()
|
| 关 键 词： | cetuximab chemotherapy colorectal cancer (CRC) efficacy 西妥昔单抗 联合化疗 结直肠癌 回顾性研究 metastatic colorectal cancer patients chemotherapy combination therapy predict especially high safe effective case infusion related reaction Neutropenia severity disease control |
| 收稿时间： | 2007-12-14 |
Retrospective study of cetuximab in combination with chemotherapy for patients with colorectal cancer |
| |
| Zhihao Lu,Xiaotian Zhang,Lin Shen,Xiaodong Zhang,Jie Li,Zhongtao Zhang. Retrospective study of cetuximab in combination with chemotherapy for patients with colorectal cancer[J]. The Chinese-German Journal of Clinical Oncology, 2008, 7(7): 400-403. DOI: 10.1007/s10330-008-0090-3 |
| |
| Authors: | Zhihao Lu Xiaotian Zhang Lin Shen Xiaodong Zhang Jie Li Zhongtao Zhang |
| |
| Affiliation: | (1) Department of GI Oncology, Peking University, School of Oncology, Beijing Cancer Hospital & Institute, Beijing, 100036, China;(2) Department of General Surgery, Beijing Youyi Hospital, Beijing, 100036, China |
| |
| Abstract: | ![]()
Objective:To evaluate the efficacy and safety of cetuximab combined with chemotherapy in colorectal cancer (CRC).Methods:35 cases of CRC were retrospectively analyzed.Efficacy and adverse events were observed.Results:29 cases of CRC were evaluated by RECIST criteria,showing 7 PR (partial response,24.1%) and 15 SD (stable disease,51.8%),disease control rate (DC) was 75.9%.Subgroup analysis showed response rate (RR) of 36.4% and DC of 91% in the 1st line therapy,RR of 20% and DC of 70% in the 2rid line therapy,RR of 12.5% and DC of 62.5% in heavily pre-treated cases.Rash appeared in 74.3% of patients (grade 3 was 8.6%),and the severity was relevant with disease control rate (DC).Neutropenia of grade 3/4 was 14.3%,and infusion related reaction (IRR) of grade 3 happened in 1 case (2.9%).Conclusion:Cetuximab combined with chemotherapy is safe and effective for patients with metastatic colorectal cancer.The combination therapy shows high DC,especially in 1st line therapy.Severity of rash may predict efficacy. |
| |
| Keywords: | cetuximab chemotherapy colorectal cancer (CRC) efficacy |
| 本文献已被 维普 万方数据 SpringerLink 等数据库收录！ |
|
